Molecular and Chemical Neuropathology

, Volume 13, Issue 3, pp 225–232 | Cite as

Urinary excretion of metabolites of norepinephrine in Tourette’s syndrome

  • Glen B. Baker
  • Robert A. Bornstein
  • Alan B. Douglass
  • Alan Carroll
  • Gordon King


Urinary excretion of the norepinephrine metabolites 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) and normetanephrine (NME) was measured in Tourette’s Syndrome (TS) patients and in control subjects matched for age and education. The 24-h excretion (expressed per gram of creatinine) of total MHPG and of free and total (free + conjugated) NME was significantly lower in TS patients than in the normal subjects.

Index Entries

3-methoxy-4-hydroxyphenylethylene glycol (MHPG) norepinephrine normetanephrine Tourette’s syndrome 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ang A., Borison R., Dysken M., and Davis J. M. (1982) Reduced excretion of MHPG in Tourette’s Syndrome,Advances in Neurology, vol. 35 (Friedhoff A. H. and Chase T. N., eds.) Raven, NY, pp. 171–175.Google Scholar
  2. Baker G. B., Bornstein R. A., Rouget A. C., Ashton S. E., van Muyden J. C., and Coutts R. T. (1990) Phenylethylaminergic mechanisms in attention deficit disorder.Biol. Psychiatry (in press).Google Scholar
  3. Baker G. B., Coutts R. T., Bornstein R. A., Dewhurst W. G., Douglass A. B., and MacDonald R. N. (1986) A rapid and sensitive gas chromatographic procedure for analysis of 3-methoxy-4-hydroxyphenylethylene glycol in urine.Res. Commun. Chem. Path. Pharmacol. 54 141–144.Google Scholar
  4. Bornstein R. A., and Baker G. B. (1988) Neuropsychological correlates of urinary amine metabolites in Tourette’s syndrome.Int. J. Neurosci. 42, 113–120.PubMedCrossRefGoogle Scholar
  5. Bornstein R. A., and Baker G. B. (1990) Urinary amines in Tourette’s syndrome patients with and without phenylethylamine abnormality.Psychiatry Res. 31, 279–286.PubMedCrossRefGoogle Scholar
  6. Bornstein R. A., Baker G. B., Carroll A., King G., and Ashton S. (1990) Phenylethylamine metabolism in Tourette’s syndrome.J. Neuropsychiat. Clin. Neurosci. 2, 408–412.Google Scholar
  7. Cassens G., Roffman M., Kuruc A., Orsulak P. J., and Schildraut J. J. (1980) Alterations in brain norepinephrine metabolism induced by environmental stimuli previously paired with inescapable shock.Science 209, 1138–1139.PubMedCrossRefGoogle Scholar
  8. Cohen D. J., Shaywitz B. A., Caparulo B. K., Young J. G., and Bowers M. B. (1978) Chronic multiple tics of Gilles de la Tourette’s disease.Arch. Gen. Psychiat. 35, 245–250.PubMedGoogle Scholar
  9. Cohen D. J., Shaywitz B. A., Young J. G., Carbonari C. M., Nathanson J. A., Lieberman D., Bowers M. B., and Maas J. W. (1979) Central biogenic amine metabolism in children with the syndrome of chronic multiple tics of Gilles de la Tourette.J. Am. Acad. Child Psychiatry 18, 320–341.PubMedCrossRefGoogle Scholar
  10. Coutts R. T., Baker G. B., LeGatt D. F., McIntosh G. J., Hopkinson G., and Dewhurst W. G. (1981) Screening for amines of psychiatric interest in urine using gas chromatography with electron-capture detection.Progr. Neuropsychopharmacol. 5, 565–568.CrossRefGoogle Scholar
  11. Davis B. A. (1989) Biogenic amines and their metabolites in body fluids of normal, psychiatric, and neurological subjects.J. Chromatogr. 466, 89–218.PubMedCrossRefGoogle Scholar
  12. Kessler J. A., Gordon E. K., Reid J. L., and Kopin I. J. (1976) Homovanillic acid and 3-methoxy-4-hydroxyphenylethylene glycol production by the monkey spinal cord.J. Neurochem. 26, 1057–1061.PubMedCrossRefGoogle Scholar
  13. Koslow S. H., and Cross C. K. (1982) Cerebrospinal fluid monoamine metabolites in Tourette syndrome and their neuroendocrine implications.Advances in Neurology (Friedhoff A. J., and Chase T. N. eds.), Raven, NY, pp. 185–197.Google Scholar
  14. Lake C. R., Ziegler M. G., Elridge R., and Murphy D. (1977) Catecholamine metabolism in Gilles de la Tourette’s syndrome.Am. J. Psychiatry 134, 257–360.PubMedGoogle Scholar
  15. Leckman J. F., Detlor J., Harcherik D. F., Young J. G., Anderson G. M., Shaywitz B. A., and Cohen D. J. (1983) Acute and chronic clonidine treatment in Tourette’s syndrome: A preliminary report on clinical response and effect on plasma and urinary catecholamine metabolites, growth hormone, and blood pressure.J. Am. Acad. Child Psychiatry 22, 433–440.PubMedGoogle Scholar
  16. Leckman J. F., Maas J. W., Redmond E. J., and Heninger G. R. (1980) Effects of oral clonidine on plasma 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG) in man: Preliminary report.Life Sci. 26, 1047–1061.CrossRefGoogle Scholar
  17. Maas J. W., Hattox S. E., Greene N. M., and Landis D. H. (1979) 3-Methoxy-4-hydroxyphenylethyleneglycol production by human brain in vivo.Science 205, 1025–1027.PubMedCrossRefGoogle Scholar
  18. Markianos E., and Beckmann H. (1976) Diurnal changes in dopamine β-hydroxylase, homovanillic acid, and 3-methoxy-4-hydroxyphenylglycol in serum of man.J. Neural Transm. 39, 79–93.PubMedCrossRefGoogle Scholar
  19. Robertson M. M. (1989) The Gilles de la Tourette syndrome: the current status.Br. J. Psychiatry 154, 147–169.PubMedCrossRefGoogle Scholar
  20. Roy A., Pickar D., DeJong J., Karoum F., and Linnoila M. (1988) Norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine.Arch. Gen. Psychiatry 45, 849–857.PubMedGoogle Scholar
  21. Sandler M., Hale A. S., Hannah P., and Bridges P. K. (1988) The tyramine conjugation test in unipolar and bipolar depressed patients: utility as a predictor of treatment response.Trace Amines: Comparative and Clinical Neurobiology (Boulton A. A., Juorio A. V., and Downer R. G. H., eds.), Humana Press, Clifton, NJ, pp. 369–377.Google Scholar
  22. Shapiro A. K., Baron M., Shapiro E. S., and Levitt M. (1984) Enzyme activity in Tourette’s syndrome.Arch. Neurol. 41, 282–285.PubMedGoogle Scholar
  23. Shapiro A. K., Shapiro E. S., Young J. G., and Feinber T. E. (1988)Gilles de la Tourette Syndrome, 2nd Ed., Raven, NY.Google Scholar
  24. Singer H. S., Trine T. E., Butler I. J., Zaczek R., and Coyle J. T. (1982) Clinical symptomatology, CSF neurotransmitter metabolites and serum haloperidol levels in Tourette syndrome,Advances in Neurology, vol. 35 (Friedhoff A. J., and Chase T. N., eds.), Raven, NY, pp. 1771–1783.Google Scholar
  25. Sweeney D., Pickar D., Redmond D. E., and Maas J. (1978) Noradrenergic and dopaminergic mechanisms in Gilles de la Tourette’s syndrome.Lancet,i, 872.CrossRefGoogle Scholar
  26. Zametkin A. J., Karoum F., Linnoila M., Rapoport J. L., Brown G. L., Chuang T. W., and Wyatt R. J. (1985) Stimulants, urinary catecholamines, and indoleamines in hyperactivity. A comparison of methylphenidate and dextroamphetamine.Arch. Gen. Psychiatry 42, 251–255.PubMedGoogle Scholar

Copyright information

© Humana Press 1991

Authors and Affiliations

  • Glen B. Baker
    • 1
  • Robert A. Bornstein
    • 2
  • Alan B. Douglass
    • 1
  • Alan Carroll
    • 1
  • Gordon King
    • 1
  1. 1.PMHAC Research Unit, Department of PsychiatryUniversity of AlbertaEdmontonCanada
  2. 2.Department of PsychiatryOhio State UniversityColumbus

Personalised recommendations